

Guidelines and Recommendations

Giovanni Lombardi*, Niklas Rye Jørgensen, Nicholas C. Harvey, Eugene V. McCloskey, Kristina E. Åkesson, Richard Eastell, Patrick Garnero, John A. Kanis, Patricia Khashayar, Nancy E. Lane, Michael R. McClung, Stuart Silverman, Konstantinos Makris, Harjit Pal Bhattoa, Samuel D. Vasikaran, Richard Pikner, Etienne Cavalier and the Joint IOF Working Group and IFCC Committee on Bone Metabolism

Guidelines for the correct use of the nomenclature of biochemical indices of bone status: a position statement of the Joint IOF Working Group and IFCC Committee on Bone Metabolism

<https://doi.org/10.1515/cclm-2024-1148>

Received October 2, 2024; accepted November 5, 2024;

published online November 25, 2024

Abstract: The presented guidelines are an update of the position paper, endorsed by the International Osteoporosis Foundation (IOF), on nomenclature of bone markers published over 2 decades ago. Novel insight into bone biology and pathophysiology of bone disorders has highlighted the increasing relevance of new and known mediators implicated in various aspects of bone metabolism. This updated guideline proposes the nomenclature Bone Status

Indices (BSI) as the comprehensive classification rather than bone turnover markers, bone markers, metabolic markers of bone turnover or metabolic markers of bone turnover, that are currently in use for the implicated molecules. On behalf of the IFCC Committee on Bone Metabolism and the Joint IOF Working Group and IFCC Committee on Bone Metabolism, the authors propose standardized nomenclature, abbreviations and measurement units for the bone status indices.

Keywords: bone status indices; standardization; nomenclature

Giovanni Lombardi and Niklas Rye Jørgensen contribute equally to the work.

Richard Pikner and Etienne Cavalier are both senior authors and contributed equally to the work.

***Corresponding author: Prof. Giovanni Lombardi**, PhD, EuSpLM, Laboratory of Experimental Biochemistry, IRCCS Ospedale-Galeazzi Sant'Ambrogio, Via Cristina Belgioioso 173, 20157, Milan, Italy; and Department of Athletics, Strength and Conditioning, Poznań University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland, E-mail: giovanni.lombardi@grupposandonato.it. <https://orcid.org/0000-0002-8365-985X>

Niklas Rye Jørgensen, Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark; and Faculty of Health and Medical Sciences, Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. <https://orcid.org/0000-0001-9624-5210>

Nicholas C. Harvey, MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK; and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. <https://orcid.org/0000-0002-8194-2512>

Eugene V. McCloskey, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK; Mellanby Centre for Musculoskeletal Research, MRC Versus Arthritis

Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK; and Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK. <https://orcid.org/0000-0003-0177-8140>

Kristina E. Åkesson, Department of Clinical Sciences, Clinical and Molecular Osteoporosis Research Unit, Lund University, Malmö, Sweden; and Department of Orthopaedics, Skåne University Hospital, Malmö, Sweden. <https://orcid.org/0000-0003-3024-2804>

Richard Eastell, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK. <https://orcid.org/0000-0002-0323-3366>

Patrick Garnero, INSERM Unit 1033, Edouard Herriot Hospital, Lyon, France. <https://orcid.org/0000-0003-0939-5099>

John A. Kanis, Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK; and Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia. <https://orcid.org/0000-0002-3129-4326>

Patricia Khashayar, International Institute for Biosensing, University of Minnesota, Minneapolis, USA. <https://orcid.org/0000-0001-7525-8418>

Nancy E. Lane, Department of Medicine, Division of Rheumatology, U.C. Davis Health, Sacramento, CA, USA

Michael R. McClung, Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia; and Oregon Osteoporosis Center, Portland, OR, USA. <https://orcid.org/0000-0002-7827-0778>

Introduction

In 2000, Pierre D. Delmas, during his term in office as the President of the International Osteoporosis Foundation (IOF), together with a group of other experts, authored an IOF endorsed position paper proposing the standardisation of the nomenclature of bone markers [1]. The main aim of the paper, also published in *Clinical Chemistry*, was “*to avoid confusion in the literature, given the growing number of various assays, especially for measurement of bone resorption*” [2, 3]. Until today, the objective of consistency and uniformity in the use of the nomenclature proposed by Delmas has not been realized. Laboratories continue to use the terms and abbreviations at their own discretion without consistency or uniformity. Furthermore, there is a lack of standardisation in naming of new markers, especially several regulatory molecules, for which various terms have been used in studies to name the same markers. An example is given by osteocalcin, that is also called bone gla-protein, and is abbreviated as OC, OCN, BGLAP [4]. This inconsistency, along with the rejection, in practice, by some journals, to use the proposed nomenclature, has compelled authors to report the various aliases pertaining to the marker studied. In the era of big data sharing, it is inconceivable that either a molecule can be called differently, or different molecules share the same name. Again, the example comes from osteocalcin: it can exist in different forms with different degree of carboxylation, from zero to three; however, these forms are overall called osteocalcin or, sometimes, uncarboxylated or undercarboxylated osteocalcin [4]. Further, the abbreviation CTX-I (carboxyterminal collagen type I cross-links) often is used indiscriminately to indicate α -CTX-I, β -CTX-I and the CTX generated by matrix metalloproteinases activity [5]. The need for uniformity in nomenclature is driven by the need for comparability of the results among studies. These and other factors justify the need for an update and revision of the previous position paper.

The first step in standardising nomenclature is the provision of a collective names for these indices. A considerable

body of literature refers to these markers as “bone turnover markers”, “bone markers”, “metabolic markers of bone turnover” or “biochemical markers of bone turnover”. Each idiom contemplates specific, but not comprehensive, aspects of the functions of the molecules involved. Indeed, the term “turnover”, specifically identifies a process of replacement of “old”, functionally impaired (or less efficient) components by newly synthesised molecules and is mainly associated with structural elements [6]. On the other hand, the term “metabolic” refers to the anabolic-versus-catabolic activity of bone cells. Even in this case it refers to the structural and enzymological aspects, completely excluding any regulatory, hormonal and elemental mediators [6]. Finally, these terms include only bone-derived molecules disregarding indices or mediators originating from other tissues and yet importantly affecting bone cell metabolism and bone matrix turnover are considered [7].

Based on these considerations we propose the alternative term Bone Status Indices (BSIs) to better embrace the entire set of molecules, including structural components, side products of either anabolic or catabolic activities, regulatory molecules, enzymatic activities, and hormones that altogether contribute to defining the status of the skeleton.

The current advances in automation and the inflexibility of laboratory software in usable characters for acronyms are other aspects to be considered. As these acronyms will be included in laboratory reports, uniformity will help readers, patients and physicians by simplifying the retrieval of related information from specialised sources and avoid potential misunderstanding and erroneous interpretations.

The updated guidelines thus take into consideration all those additional indices that are related to bone status but do not originate from the bone.

Finally, the issue of measurement units, although not directly related to the nomenclature, is associated to the need of standardisation of laboratory reports. As for indices' names, the units frequently used mostly reflect habits, often at the national level, and very often do not adhere to the standards of the International System of Units (SI).

Stuart Silverman, Cedars-Sinai Medical Center and Geffen School of Medicine UCLA, Los Angeles, CA, USA. <https://orcid.org/0000-0002-5313-1018>

Konstantinos Makris, Clinical Biochemistry Department, KAT General Hospital, Kifissia, Athens, Greece; and Laboratory for the Research of Musculoskeletal System “Th. Garofalidis”, School of Medicine, National and Kapodistrian, University of Athens, Athens, Greece. <https://orcid.org/0000-0002-7896-9028>

Harjit Pal Bhattoa, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. <https://orcid.org/0000-0002-4909-0065>

Samuel D. Vasikaran, PathWest Laboratory Medicine, Fiona Stanley Hospital, Murdoch, WA, Australia. <https://orcid.org/0000-0002-0831-3031>

Richard Pikner, Department of Clinical Biochemistry and Bone Metabolism, Klatovska Hospital, Klatovy, Czech Republic; Department of Clinical Biochemistry and Haematology, Faculty of Medicine Pilsen, Charles University Prague, Pilsen, Czech Republic; and Faculty of Health Care Studies, University of West Bohemia, Pilsen, Czech Republic. <https://orcid.org/0000-0002-0633-8876>

Etienne Cavalier, Department of Clinical Chemistry, CIRM, University of Liège, CHU de Liège, Belgium. <https://orcid.org/0000-0003-0947-2226>

Table 1: Recommended nomenclature (and related acronyms), grouping and measurement unit for BSIs.

Category	Group/Family	Recommended name [UniProt/Expasy recommended name, UniProt/Expasy/PubChem ID] ^a	Used acronyms (acronyms marked with ^b are explained in the footnote)	Recommended acronym	Recommended unit
Bone turnover markers	Type I collagen propeptides	Procollagen type I N-propeptide	P1NP, P1NP	P1NP	µg/L
		Intact procollagen type I N-propeptide (trimer)	Intact P1NP, intact P1NP, iP1NP, iP1NP	iP1NP	µg/L
		Procollagen type I N-propeptide (trimer + monomer)	Total P1NP, total P1NP, tP1NP, tP1NP	tP1NP	µg/L
		Procollagen type I C-propeptide	P1CP, P1CP	P1CP	µg/L
	Type I collagen cross-linked telopeptides	N-terminal telopeptide of type I collagen	NTX-I, NTX-1, NTX-I, NTX-1	NTX-I	µg/L (serum/plasma, urine)
		α-isomerized C-terminal telopeptide of type I collagen	α-CTX-I, α-CTX-I, α-CTX-1, α-CTX-1, αCTX-I, αCTX-I, αCTX-1, αCTX-1, alphaCTX-I, alphaCTX-I, alphaCTX-1	α-CTX-I (α-CTX-I) ^e	µg/L (serum/plasma/urine)
		β-isomerized C-terminal telopeptide of type I collagen	β-CTX-I, β-CTX-I, β-CTX-1, β-CTX-1, βCTX-I, βCTX-I, βCTX-1, βCTX-1, betaCTX-I, betaCTX-I, betaCTX-1, crosslaps, beta crosslaps	β-CTX-I (β-CTX-I) ^e	ng/L
		C-terminal cross-linking telopeptide of type I collagen generated by MMPs (matrix metalloproteinases)	CTX-MMP, ICTP	CTX-I-MMP	µg/L
		(Total tissue non-specific alkaline phosphatase [UniProt: Alkaline phosphatase, tissue-nonspecific isozyme-P05186])	ALP, tnsALP, AP, TNAP	ALP	U/L
	Alkaline phosphatase				
		Bone-specific alkaline phosphatase (mass concentration)	BALP, bone ALP, BAP, BSAP	BALP	µg/L
		Bone-specific alkaline phosphatase (catalytic activity)			U/L
		Acid phosphatase [UniProt: Tartrate-resistant acid phosphatase type 5-P13686]	ACP	ACP	U/L
		Tartrate-resistant acid phosphatase isoform 5b [UniProt: Tartrate-resistant acid phosphatase type 5-P13686]	TRACP5b, TRAP5b	TRACP5b	U/L
	Acid phosphatase				
Regulatory molecules	Cathepsin K	Cathepsin K [UniProt: Cathepsin K-P43235]	CTSK	CTSK	µg/L
	Osteocalcin forms ^c	Osteocalcin (total)	OC, OCN, BGLAP, B-GLAP, bone-gla-protein	OC	µg/L
		Intact osteocalcin [UniProt: Osteocalcin-P02818]	iOC, intact OC	iOC	µg/L
		N-mid fragment of osteocalcin	NmidOC, Nmid-OC, N-ter-mid OC	NmidOC	µg/L
		Fully carboxylated osteocalcin	/	γ ₃ OC (g ₃ OC) ^e	µg/L
		Undercarboxylated osteocalcin	/	γ ₂ OC (g ₂ OC) ^e γ ₁ OC (g ₁ OC) ^e	µg/L
		Uncarboxylated osteocalcin	/	γ ₀ OC (g ₀ OC) ^e	µg/L

Table 1: (continued)

Category	Group/Family	Recommended name [UniProt/Expaty recommended name, UniProt/Expaty/PubChem ID] ^a	Used acronyms (acronyms marked with ^b are explained in the footnote)	Recommended acronym	Recommended unit
Vitamin D metabolites	Vitamin D (total)	Vitamin D ₂ (ergocalciferol, PubChem CID: 5280793)	vitD ₂	vitD ₂	nmol/L, µg/L
		Vitamin D ₃ (cholecalciferol, PubChem CID: 5280795)	vitD ₃	vitD ₃	
	Calcidiol	25-(OH) vitamin D (total)	25-(OH)D	25-(OH)D	nmol/L, µg/L
		25-(OH) vitamin D ₂ (25-hydroxyergocalciferol, PubChem CID: 5710148)	25-(OH)D ₂	25-(OH)D ₂	
		25-(OH) vitamin D ₃ (25-hydroxycholecalciferol, PubChem CID: 5283731)	25-(OH)D ₃	25-(OH)D ₃	
	Free calcitriol	Free 25-(OH) vitamin D (total)	f25-(OH)D	f25-(OH)D	pmol/L, ng/L
		free 25-(OH) vitamin D ₂ (free 25-hydroxyergocalciferol, PubChem CID: 5710148)	f25-(OH)D ₂	f25-(OH)D ₂	
		free 25-(OH) vitamin D ₃ (free 25-hydroxycholecalciferol, PubChem CID: 5283731)	f25-(OH)D ₃	f25-(OH)D ₃	
	Calcitriol	1,25-(OH) ₂ vitamin D (total)	1,25-(OH) ₂ D	1,25-(OH) ₂ D	pmol/L, ng/L
		1,25-(OH) ₂ vitamin D ₂ (1,25-dihydroxyergocalciferol, PubChem CID: 129846083)	1,25-(OH) ₂ D ₂	1,25-(OH) ₂ D ₂	
		1,25-(OH) ₂ vitamin D ₃ (1,25-dihydroxycholecalciferol, PubChem CID: 5280453)	1,25-(OH) ₂ D ₃	1,25-(OH) ₂ D ₃	
	Free calcitriol	Free 1,25-(OH) ₂ vitamin D (total)	f1,25-(OH) ₂ D	f1,25-(OH) ₂ D	pmol/L, ng/L
		free 1,25-(OH) ₂ vitamin D ₂ (free 1,25-dihydroxyergocalciferol, PubChem CID: 129846083)	f1,25-(OH) ₂ D ₂	f1,25-(OH) ₂ D ₂	
		free 1,25-(OH) ₂ vitamin D ₃ (free 1,25-dihydroxycholecalciferol, PubChem CID: 5280453)	f1,25-(OH) ₂ D ₃	f1,25-(OH) ₂ D ₃	
	24,25-(OH) ₂ vitamin D (total)	24,25-(OH) ₂ vitamin D ₂ ((24R)-dihydroxyergocalciferol, PubChem CID: 6438393)	24,25-(OH) ₂ D ₂	24,25-(OH) ₂ D ₂	nmol/L, µg/L
		24,25-(OH) ₂ vitamin D ₃ ((24R)-dihydroxycholecalciferol, (24R)-hydroxycalcidiol, PubChem CID: 6434253)	24,25-(OH) ₂ D ₃	24,25-(OH) ₂ D ₃	
	3-epi-25-(OH) vitamin D (total)	3-epi-25-(OH) vitamin D ₂ (3-epi-25-hydroxyergocalciferol, PubChem CID: 585790)	3-epi-25-(OH)D ₂	3-epi-25-(OH)D ₂	nmol/L, µg/L
		3-epi-25-(OH) vitamin D ₃ (3-epi-25-hydroxycholecalciferol, PubChem CID: 13080214)	3-epi-25-(OH)D ₃	3-epi-25-(OH)D ₃	

Table 1: (continued)

Category	Group/Family	Recommended name [UniProt/Expaty recommended name, UniProt/Expaty/PubChem ID] ^a	Used acronyms (acronyms marked with ^b are explained in the footnote)	Recommended acronym	Recommended unit
		1,24,25-(OH) ₃ vitamin D (total)	1,24,25-(OH) ₃ D	1,24,25-(OH) ₃ D	pmol/L, ng/L
		1,24,25-(OH) ₃ vitamin D ₂ (1,24,25-trihydroxyergocalciferol, PubChem CID: 9547253)	1,24,25-(OH) ₃ D ₂	1,24,25-(OH) ₃ D ₂	
		1,24,25-(OH) ₃ vitamin D ₃ (1,24,25-trihydroxycholecalciferol, PubChem CID: 6439591)	1,24,25-(OH) ₃ D ₃	1,24,25-(OH) ₃ D ₃	
		25-(OH) vitamin D-26,23-lactone (total)	25-(OH)D-26,23-lactone	25-(OH)D-26,23-lactone	nmol/L, µg/L
		25-(OH) vitamin D ₂ -26,23-lactone	25-(OH)D ₂ -26,23-lactone	25-(OH)D ₂ -26,23-lactone	
		25-(OH) vitamin D ₃ -26,23-lactone	25-(OH)D ₃ -26,23-lactone	25-(OH)D ₃ -26,23-lactone	
		Vitamin D-binding protein [UniProt: Vitamin D-binding protein-P02774]	VDBP, VBP, VitD-BP, DBP, VDB	VDBP	µmol/L
	Parathyroid hormone	Parathyroid hormone (previously intact PTH) [UniProt: Parathyroid hormone-P01270]	PTH, intact PTH, iPTH	PTH	pmol/L, ng/L
		1-84 Parathyroid hormone	1-84PTH, PTH1-84, PTH(1-84)	1-84PTH	pmol/L, ng/L
	Fibroblast growth factor 23	Intact fibroblast growth factor 23 [UniProt: Fibroblast growth factor 23-Q9GZV9]	iFGF23, intact FGF23	iFGF23	ng/L
		C-terminal FGF23	cFGF23, C-terminal FGF23, C-ter FGF23	cFGF23	RU/L ^d
	Wnt signalling pathway inhibitors	Sclerostin [UniProt: Sclerostin-Q9BQB4]	Sclerostin, SOST	Sclerostin	ng/L
		Dickkopf-related protein 1 [UniProt: Dickkopf-related protein 1-O94907]	Dkk-1, Dkk1, DKK-1, DKK1	DKK-1	ng/L
	Tumour necrosis factor superfamily	Receptor activator of nuclear factor κB ligand [UniProt: Tumour necrosis factor ligand superfamily member 11-O14788]	RANKL, TNFSF11 ^b , TRANCE ^b , OPG ^b , ODF ^b	RANKL	ng/L
		Receptor activator of nuclear factor κB [UniProt: Tumour necrosis factor receptor superfamily member 11A-Q9Y6Q6]	RANK, TNFRSF11A ^b , TRANCE receptor	RANK	µg/L
		Osteoprotegerin [UniProt: Tumour necrosis factor receptor superfamily member 11B-O00300]	OPG, TNFRSF11B ^b , OCIF ^b	OPG	ng/L
		Secreted protein acidic and rich in cysteine [UniProt: SPARC-P09486]	SPARC, osteonectin, ON ^b , BM-40 ^b	SPARC	ng/L
	Factors involved in cell migration and adhesion	Osteopontin [UniProt: Osteopontin-P10451]	OPN, BSP-1 ^b , BNSP ^b , ETA-1 ^b , SPP1 ^b , Ric ^b	OPN	ng/L
		Periostin [UniProt: Periostin-Q15063]	PSTN, POSTN, PN, OSF-2 ^b	PSTN	ng/L
		Periostin fragment generated by cathepsin K	kPSTN, kPOSTN	kPSTN	µg/L

^aIf available. ^bTNFSF11, tumour necrosis factor ligand superfamily member 11; TRANCE, TNF-related activation-induced cytokine; OPG, osteoprotegerin ligand; ODF, osteoclast differentiation factor; TNFRSF11A, tumour necrosis factor receptor superfamily member 11A; TNFRSF11B, tumour necrosis factor receptor superfamily member 11B; OCIF, osteoclastogenesis inhibitory factor; ON, osteonectin; BM-40, basement-membrane protein 40; BSP-1, bone sialoprotein 1; BNSP, bone sialoprotein; ETA-1, early T-lymphocyte activation 1; SPP1, secreted phosphoprotein 1; Ric, Ricketsia resistance; OSF-2, osteoblast-specific factor 2. ^cNomenclature is referred to the commercially available assays. ^dThis is a procedure-defined unit. ^eIn case the IT, system does not allow to use the Greek letters, it possible to substitute them with the Latin counterpart.

Table 2: Conversion formulas for vitamin D metabolites.

Analyte	MW	Conversion formulas
vitamin D ₂ (ergocalciferol)	396.60	nmol/L=2.52 * µg/L
vitamin D ₃ (cholecalciferol)	384.60	nmol/L=2.60 * µg/L
25-(OH) vitamin D ₂	412.60	nmol/L=2.42 * µg/L
25-(OH) vitamin D ₃	400.64	nmol/L=2.50 * µg/L
free 25-(OH) vitamin D ₂	412.60	pmol/L=2.42 * ng/L
free 25-(OH) vitamin D ₃	400.64	pmol/L=2.50 * ng/L
1,25-(OH) ₂ vitamin D ₂	428.60	pmol/L=2.33 * ng/L
1,25-(OH) ₂ vitamin D ₃	416.60	pmol/L=2.40 * ng/L
free 1,25-(OH) ₂ vitamin D ₂	428.60	pmol/L=2.33 * ng/L
free 1,25-(OH) ₂ vitamin D ₃	416.60	pmol/L=2.40 * ng/L
24,25-(OH) ₂ vitamin D ₂	429.00	nmol/L=2.33 * µg/L
24,25-(OH) ₂ vitamin D ₃	416.63	nmol/L=2.40 * µg/L
3-epi-25-(OH) vitamin D ₂	412.65	nmol/L=2.42 * µg/L
3-epi-25-(OH) vitamin D ₃	400.64	nmol/L=2.50 * µg/L
1,24,25-(OH) ₃ vitamin D ₂	444.64	pmol/L=2.25 * ng/L
1,24,25-(OH) ₃ vitamin D ₃	432.60	pmol/L=2.31 * ng/L
25-(OH) vitamin D ₂ -26,23-lactone	440.60	nmol/L=2.27 * µg/L
25-(OH) vitamin D ₃ -26,23-lactone	428.60	nmol/L=2.25 * µg/L

The aim of this report, written on behalf of the Joint International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Bone Metabolism and the IOF Working Group on Bone Metabolism, is to propose a comprehensively revised nomenclature of the BSIs with appropriate abbreviations as well as the correct measurement unit, based on the indication of the SI. As described above, the field of bone-related markers has been enlarged, in the last years, to newly discovered molecules and to already known mediators with newly discovered roles in bone structure and metabolism. Most of these are currently used in diagnostics while others have a diagnostic potential that might justify their clinical implementation in the future. Therefore, since the variety of roles and origin of the components which measurements are useful in determining the bone status, nomenclature and related issues will be treated separately for three main groups of markers: i) bone turnover markers, ii) bone cells' enzymes and iii) regulatory molecules.

Recommended nomenclature for bone status indices (BSIs)

Bone status indices (BSIs) have been categorised based on the general process they belong to: i) bone turnover markers, ii) bone cells' enzymes or iii) regulatory molecules.

Table 1 reports the main information related to grouping, nomenclature and recommended units of measurement.

Comments on Tables

Here are some considerations that should be taken into account for a correct contextualization of the information reported in Table 1.

- CTX-I corresponds to the C-terminal octapeptide sequence of α1 chain of type I collagen (EKAHDGGR) [8]. β-CTX-I (EKAHD-β-GGR) results from the β-isomerization of α-CTX-I, i.e., transfer of the peptide bond between aspartic acid (D) residues and the adjacent amino acid from the α-carboxyl group to the β-carboxyl group. The ratio between native (α-CTX-I) and isomerized β-CTX-I estimates the extent of type I collagen isomerization in bone. Due to high turnover in growing subjects, the equilibrium of isomerization cannot be achieved, resulting in a relatively higher α/β-CTX-I; once reached the peak bone mass (>20 years of age) since the rate of bone remodelling is slower than isomerization, the equilibrium is achieved, resulting in a fairly constant α/β-CTX-I ratio [9]. α-CTX-I and β-CTX-I can be used in case the IT system does not allow to use the Greek letters.
- The CTX-I-MMP epitope (GPPSAGFDFSFLPQQPE-KAHDGGR) is a larger conformational epitope, than CTX-I, including at least two telopeptides and the first phenylalanine (F) of the phenylalanine-rich region; cathepsin K degrades CTX-I-MMP to generate CTX-I [10].
- The term CTX-I-MMP is recommended instead of C-terminal telopeptide of type I collagen (ICTP).
- Since BALP is an enzyme, the activity should be measured. However, due to the heterogeneity of the commercially available assay kits, measurement in terms of mass concentration is acceptable. Based on UK-NEQAS results, U/L could be converted into µg/L, and *vice versa*, according to the following equations [11]:

$$\mu\text{g/L} = \text{U/L} \cdot 0.504$$

$$\text{U/L} = \mu\text{g/L} \cdot 1.984$$

However, the use of these equations is strongly discouraged since their reliability is scarce.

- Osteocalcin exists in the circulation in different forms, associated with a different degree of carboxylation and/or resulting from proteolytic cleavage that can be assessed by different assays [4]. Therefore, the term osteocalcin (OC) refers to the total amount of OC, i.e., the sum of intact and fragmented OC fractions regardless of their degree of carboxylation. The terms iOC and NmidOC refers only to the intact and the N-terminal plus the mid-fragment (the most abundant circulating fragment), respectively.

Regarding the carboxylation in position γ ("g" can be used in case the IT system does not allow to use the Greek letters) of the glutamic acid residues (19, 21 and 24), the two limit forms should be named $\gamma_3\text{OC}$ ($g_3\text{OC}$), the fully carboxylated one, and $\gamma_0\text{OC}$ ($g_0\text{OC}$), the fully uncarboxylated one. Finally, the intermediate forms of carboxylation, i.e., those bearing either 1 or 2 carboxylic groups, should be named $\gamma_1\text{OC}$ ($g_1\text{OC}$) and $\gamma_2\text{OC}$ ($g_2\text{OC}$), respectively, regardless of the position of the glutamic acid residue(s) within the protein sequence.

- Vitamin D metabolites mass concentration must be expressed as nmol/L or $\mu\text{g/L}$ and pmol/L or ng/L, according to [12]. Traditional units, such as ng/mL or pg/mL should be avoided. Vitamin D metabolites ratios (VMRs) are calculated parameters. It is recommended to measure both analytes simultaneously in one sample using the same analytical technique, preferably LC-MS/MS [13]. To unify VMRs' results, we recommend the expression as a % for the following VMRs, although recently often used ratios are opposite to and in absolute values [14]. The term VMR is often used for 24,25-(OH) $_2$ D/25-(OH)D ratio but due to possible confusion with others VMRs, the metabolite type should be always mentioned, e.g., VMR (24,25/25) [15, 16].

Use mass concentration units for VMR calculations.

$$\text{VMR (24,25/25)} = 24,25 - (\text{OH})_2\text{D} / 25 - (\text{OH})\text{D} * 100 (\text{in}\%)$$

$$\text{VMR (1,25/25)} = 1,25 - (\text{OH})_2\text{D} / 25 - (\text{OH})\text{D} * 100 (\text{in}\%)$$

$$\text{VMR (1,25/24,25)} = 1,25 - (\text{OH})_2\text{D} / 24,25 - (\text{OH})_2\text{D} * 100 (\text{in}\%)$$

Table 2 reports the conversion formulas ($\mu\text{g/L}$ to nmol/L and ng/L to pmol/L) for vitamin D metabolites.

- Intact PTH is a misleading term now and should no longer be used. Parathyroid hormone (PTH) term includes 2nd generation PTH assays (intact PTH) that use detection antibodies against N-terminus (amino acids 12–24 or 26–32). For immunoassays, the term 1-84PTH is reserved for 3rd generation PTH assays (bioactive PTH or whole PTH) that use detection antibodies against N-terminus (amino acids 1–4). These assays also cross-react with amino-PTH. PTH and 1-84PTH assays results differ significantly, at least in standards used and therefore we recommend to use terms PTH for 2nd generation PTH assays and 1-84PTH for 3rd generation PTH assays. For fragments measured by LC-MS/MS or HRMS, the measured fragments should be stated in brackets, e.g., (x–y)PTH. Use following PTH conversion factors:

$$\text{pmol/L} = \text{ng/L} * 0.106045 \text{ and } \text{ng/L} = \text{pmol/L} * 9.43$$

Conclusions

In this paper, we propose a revised guideline for the nomenclature of circulating markers useful to monitor both the metabolic activity of bone cells and the regulatory mediators that intervene in different aspects of bone cell biology, from differentiation, to migration, mechanosensing, mineral metabolism, and extracellular matrix dynamics.

Considering the diverse role of these compounds, the general terms bone turnover markers and metabolic markers of bone turnover no longer fully cover their biological roles. Therefore, the term Bone Status Indices (BSIs) is proposed as a more comprehensive terminology.

Acknowledgments: The authors would like to thank the members of the Joint IOF Working Group and IFCC Committee on Bone Metabolism: Vincent Delatour, Karen Phinney, and Cathie Sturgeon (consultants); Markus Herrmann, Jean-Paul Cristol, Edgard Delvin, Masakazu Miura, Aylin Sepici Dincel and Galina Zemtsovskaja (national representatives); Kristina Åkesson, Nasser Al-Daghri, Cyrus Cooper, Richard Eastell, Joseph Foldes, Patrick Garnero, John A. Kanis, Patricia Khashayar, Nancy Lane, Michael McClung, Stuart Silverman. Members of the IFCC Scientific Committee on Nomenclature, Properties and Units (C-NPU) in collaboration with International Union of Pure and Applied Chemistry (IUPAC): Young Bae Hansen, Rebecca Ceder, Sridevi Deveraj, Koh Furuta, Fatma Meric Yilmaz, Gunnar Nordin; Aracelis Germán, Naohito Ishii, Dalius Vitkus, Aaron Ojule, Karin Toska, Valentina Naztmudinova, Nada Majkic-Singh, Carlos Lacava (consultants and national representatives). The authors are grateful to the International Osteoporosis Foundation (IOF) Committee of Scientific Advisors for their endorsement of this position paper.

Research ethics: Not applicable.

Informed consent: Not applicable.

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Use of Large Language Models, AI and Machine Learning Tools: None declared.

Conflict of interest: The authors state no conflict of interest related to this article.

Research funding: None declared.

Data availability: Not applicable.

References

1. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J, Committee of Scientific Advisors of the International Osteoporosis Foundation. The

- use of biochemical markers of bone turnover in osteoporosis. *Osteoporos Int* 2000;11:S2–17.
2. Delmas PD. Committee of scientific advisors of the international osteoporosis. Bone marker nomenclature. *Bone* 2001;28:575–6.
 3. Delmas PD. Standardization of bone marker nomenclature. *Clin Chem* 2001;47:1497.
 4. Lombardi G, Perego S, Luzi L, Banfi G. A four-season molecule: osteocalcin. Updates in its physiological roles. *Endocrine* 2015;48:394–404.
 5. Ladang A, Rauch F, Delvin E, Cavalier E. Bone turnover markers in children: from laboratory challenges to clinical interpretation. *Calcif Tissue Int* 2023;112:218–32.
 6. Cremers S, Garnero P, Seibel MJ. Chapter 87 – biochemical markers of bone metabolism. In: Bilezikian JP, Raisz LG, Martin TJ, editors. *Principles of Bone Biology*. 3rd ed. San Diego: Academic Press; 2008:1857–81 pp.
 7. Glendenning P, Chubb SAP, Vasikaran SD. Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults. *Clin Chim Acta* 2018;481:161–70.
 8. Vasikaran SD, Miura M, Pikner R, Bhattoa HP, Cavalier E. Practical considerations for the clinical application of bone turnover markers in osteoporosis. *Calcif Tissue Int* 2023;112:148–57.
 9. Garnero P. The contribution of collagen crosslinks to bone strength. *BoneKey Rep* 2012;1:182.
 10. Garnero P, Ferreras M, Karsdal MA, Nicamhlaibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. *J Bone Miner Res* 2023;18:859–67.
 11. Cavalier E, Souberbielle JC, Gadiisseur R, Dubois B, Krzesinski JM, Delanaye P. Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. *Clin Biochem* 2014;47:1227–30.
 12. Hansen YBL. Recommendations on measurement units – why and how. *Eur J IFCC* 2019;30:250–75.
 13. Alonso N, Zelzer S, Eibinger G, Herrmann M. Vitamin D metabolites: analytical challenges and clinical relevance. *Calcif Tissue Int* 2023;112: 158–77.
 14. Tang JCY, Jackson S, Walsh NP, Greeves J, Fraser WD, Ball N, et al. Bioanalytical Facility team. The dynamic relationships between the active and catabolic vitamin D metabolites, their ratios, and associations with PTH. *Sci Rep* 2019;9:6974.
 15. Dugar A, Hoofnagle AN, Sanchez AP, Ward DM, Corey-Bloom J, Cheng JH, et al. The vitamin D metabolite ratio (VMR) is a biomarker of vitamin D status that is not affected by acute changes in vitamin D binding protein. *Clin Chem* 2023;69:718–23.
 16. Cavalier E, Fraser CG, Bhattoa HP, Heijboer AC, Makris K, Vasikaran S, et al. the IFCC-IOF Committee for Bone Metabolism. Analytical performance specifications for the measurement uncertainty of 24,25-dihydroxyvitamin D examinations. *Clin Chem Lab Med* 2023;61: 1561–6.